SRT501 Shows Oral Effectiveness in Mice for MS Eye Disease

In a new study on mice, Sirtris Pharmacueticals will present today that its SRT501 drug candidate is equally effective when administered orally versus previous studies by injection in the treatment of an eye disease common in patients with multiple sclerosis (the report of the study was originally released on March 4th, 2008). The company continues to accumulate data with the goal of validating the belief that the targeting of the sirtuin genes has the potential to become a platform for drug development in the treatment of multiple diseases of the aging.